#USA #Emeryville #Slingshot Biosciences #synthetic cell mimic #Jim Snook

Slingshot Biosciences Strengthens Leadership with Appointment of Jim Snook

EMERYVILLE, Calif. — March 5, 2026 – Slingshot Biosciences, recognized for its groundbreaking synthetic cell mimic technology that revolutionizes flow cytometry controls, has appointed Jim Snook as Senior Vice President of Global Sales. With over 20 years of executive experience in the life sciences industry, Snook’s appointment comes at a pivotal moment as the company seeks to accelerate its global expansion.

In his new role, Snook will oversee Slingshot Biosciences’ global sales team, which includes Business Development Vice Presidents, Inside Sales and Distribution Managers, and Field Application Scientists. His extensive background in commercial leadership is notable, having most recently served as Vice President of Commercial for the Protein Sciences division at Bio-Techne. Here, he was instrumental in transforming the sales structure to drive market share and stimulate growth.

Before his tenure at Bio-Techne, Snook significantly contributed to the success of Miltenyi Biotec, where he led the commercial team across the Americas. Under his leadership, the company attained market leadership in cell and gene therapy manufacturing and analytical solutions, setting a high standard in the industry.

Glenn Bilawsky, the CEO of Slingshot Biosciences, stated, “Jim’s appointment is a critical step for us as we advance our global growth strategy. His proven ability to build high-performing sales teams and generate substantial revenue growth at top-tier life sciences companies positions him perfectly to drive our commercial initiatives forward.” Bilawsky is confident that Snook's deep expertise in flow cytometry and cell therapies will help expand the company’s influence and service capability across international markets.

The demand for Slingshot’s innovative synthetic cell mimic platform is witnessing rapid growth as pharmaceutical companies, biotechnology firms, clinical diagnostics laboratories, and academic research institutions increasingly adopt it for their operations. Snook’s role will be vital in leveraging this momentum and fulfilling the surging need for reliable, reproducible biomarker controls essential for effective cell-based assay development and cell therapy production.

Expressing his enthusiasm, Jim Snook remarked, “I am excited to join Slingshot Biosciences during such a transformative phase for the company. Their platform addresses key challenges in the complex arena of cell analysis, from robust assay development to scalable deployment. The solutions we offer hold significant potential for the flow cytometry community, and I look forward to collaborating with our consultative team to deliver this technology to researchers and laboratories globally.”

About Slingshot Biosciences

As a pioneer in the life sciences sector, Slingshot Biosciences aims to enhance the quality and reliability of cell-based assays. The company specializes in providing precise and reproducible synthetic controls, which are crucial for accelerating scientific discoveries and improving patient outcomes. Their patented technology merges advanced polymer chemistry with the accuracy of semiconductor manufacturing to create synthetic cell mimics. These mimics not only ensure exceptional reproducibility and stability but also offer substantial cost efficiencies compared to traditional biological controls.

With a commitment to serving a diverse range of customers—including those in pharmaceuticals, biotechnology, clinical diagnostics, and academic research—Slingshot Biosciences is poised to make significant contributions to advancements in the industry. For further information, visit www.slingshotbio.com.